FDA Proposes Liver, GI Risk Warnings For OTC Pain Relievers
This article was originally published in The Tan Sheet
Executive Summary
FDA proposes adding warnings on labeling for OTC pain relievers to advise consumers of "potential health risks" associated with acetaminophen and NSAIDs such as aspirin, ibuprofen and naproxen
You may also be interested in...
Proposed OTC Acetaminophen Warnings Not Supported By Science – McNeil
Existing science on the safety and efficacy of OTC acetaminophen does not substantiate several FDA-proposed warnings to be included in labeling for the analgesic, McNeil Consumer Healthcare asserts
Proposed OTC Acetaminophen Warnings Not Supported By Science – McNeil
Existing science on the safety and efficacy of OTC acetaminophen does not substantiate several FDA-proposed warnings to be included in labeling for the analgesic, McNeil Consumer Healthcare asserts
Proposed OTC Acetaminophen Warnings Not Supported By Science – McNeil
Existing science on the safety and efficacy of OTC acetaminophen does not substantiate several FDA-proposed warnings to be included in labeling for the analgesic, McNeil Consumer Healthcare asserts